Lyell Immunopharma (NASDAQ:LYEL) Shares Gap Up – What’s Next?

Shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL) gapped up before the market opened on Friday . The stock had previously closed at $24.12, but opened at $25.81. Lyell Immunopharma shares last traded at $25.5950, with a volume of 3,805 shares traded.

Analyst Ratings Changes

A number of brokerages have commented on LYEL. HC Wainwright upgraded Lyell Immunopharma from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $20.00 to $45.00 in a research report on Tuesday, December 9th. Weiss Ratings reissued a “sell (d-)” rating on shares of Lyell Immunopharma in a report on Wednesday, October 8th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $45.00.

Lyell Immunopharma Trading Down 0.1%

The stock has a market capitalization of $548.52 million, a P/E ratio of -1.12 and a beta of -0.13. The firm’s fifty day moving average is $26.98 and its 200-day moving average is $18.14.

Lyell Immunopharma (NASDAQ:LYEL) last posted its quarterly earnings data on Wednesday, November 12th. The company reported ($2.13) earnings per share for the quarter, topping the consensus estimate of ($2.81) by $0.68. Lyell Immunopharma had a negative net margin of 794,292.69% and a negative return on equity of 96.68%. The company had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.01 million. Equities research analysts expect that Lyell Immunopharma, Inc. will post -0.78 EPS for the current year.

Hedge Funds Weigh In On Lyell Immunopharma

Several institutional investors have recently bought and sold shares of the business. Millennium Management LLC boosted its stake in Lyell Immunopharma by 140.0% in the third quarter. Millennium Management LLC now owns 125,361 shares of the company’s stock worth $2,036,000 after purchasing an additional 73,132 shares in the last quarter. Foresite Capital Management V LLC raised its holdings in shares of Lyell Immunopharma by 17.3% in the third quarter. Foresite Capital Management V LLC now owns 477,078 shares of the company’s stock valued at $7,748,000 after buying an additional 70,426 shares during the last quarter. ARCH Venture Management LLC lifted its position in Lyell Immunopharma by 51.5% during the 3rd quarter. ARCH Venture Management LLC now owns 2,759,072 shares of the company’s stock worth $44,807,000 after buying an additional 938,438 shares in the last quarter. Two Sigma Investments LP grew its holdings in Lyell Immunopharma by 107.0% during the 3rd quarter. Two Sigma Investments LP now owns 20,827 shares of the company’s stock worth $338,000 after acquiring an additional 10,768 shares during the last quarter. Finally, Takeda Pharmaceutical Co. Ltd. increased its position in Lyell Immunopharma by 33.3% in the 3rd quarter. Takeda Pharmaceutical Co. Ltd. now owns 54,887 shares of the company’s stock valued at $891,000 after acquiring an additional 13,722 shares in the last quarter. Institutional investors own 66.05% of the company’s stock.

Lyell Immunopharma Company Profile

Lyell Immunopharma is a clinical-stage biotechnology company focused on developing next-generation T cell therapies for cancer. Leveraging a proprietary platform that combines cell therapy, gene editing and molecular discovery, Lyell seeks to overcome key barriers in the treatment of solid tumors. The company’s approach centers on engineering T cells to enhance their persistence, functionality and resistance to the immunosuppressive tumor microenvironment.

The company’s pipeline includes multiple autologous T cell programs engineered to target tumor-associated antigens in solid malignancies such as melanoma, ovarian and pancreatic cancers.